Market Capitalization

Canadian biotech Satellos Bioscience seeks a Nasdaq listing and a $50M public offering to advance its promising muscle regeneration drug for Duchenne.

Tamarack Resort launches new multi-million dollar townhomes, marking a new chapter in Idaho's booming luxury mountain living and resort development.

A health-tech firm with a mission for free care and a $1.3B valuation eyes a Nasdaq listing, but its revenue-free history raises critical questions.

Everbright Digital hopes a 1-for-16 reverse stock split will save its Nasdaq listing, but the move raises questions about its metaverse-focused future.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

Volvo Cars' Q4 profits fell, but a tough cost-cutting plan boosted cash flow, setting the stage for its critical electric vehicle push in a tough market.

The semiconductor giant posted a huge Non-GAAP profit but a stunning IFRS loss for 2025. What's behind the numbers and why are investors cheering?

Sila Realty Trust sets its 2025 earnings date. Investors are watching to see if its strategic acquisitions and dividend policy signal strength for the sector.

In a surprise move, Sun Communities' new CFO is out after less than 30 days. His predecessor steps back in, aiming to calm markets amid a search.

With its lead drug MOLBREEVI under FDA review, Savara's upcoming investor talks are a critical test of its path from clinical trials to market.

As AI's power needs skyrocket, GridAI brings in veteran Tim Healy to lead its charge. Can his software-first approach solve the grid's biggest challenge?

Automotive seating giant Adient boosts its 2026 forecast, banking on strong North American production and operational gains, despite a reported net loss.

With promising new pipeline data and a major earnings report looming, Aclaris Therapeutics heads to two investor summits, placing its strategy on display.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

With an $80M backlog and a new 'Buy' rating, cybersecurity firm Cycurion looks poised for growth. But can it overcome its volatile past and prove its worth?

The iconic basketball-playing dog is back! Cineverse and Air Bud Entertainment are betting on nostalgia and a new story to relaunch a beloved franchise.

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

Amid a historically slow 2025 housing market, proptech firm Orchard reports 40% growth and lands $30M, proving its new marketplace model's resilience.

Powersports giant Massimo Group's stock plummets after announcing a bold but risky plan to acquire an AI firm and enter the health robotics market.

Celanese completes a key divestiture to tackle its massive debt, while buyer Element Solutions bolsters its high-growth electronics portfolio.